Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield-OK Drug List Coverage & PA …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - OklahomaPolicy N/A

    Pharmacy drug list and coverage rules (Drug List)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Oklahoma policy alerts

    Know when Blue Cross Blue Shield - Oklahoma releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the Blue Cross Blue Shield of Oklahoma pharmacy drug list structure, coverage considerations (including prior authorization, step therapy, quantity limits, specialty drug handling), and processes for exceptions and member/provider resources. Applies to members and prescribing providers using BCBSOK pharmacy benefits.

    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyPharmacy drug list and coverage rules (Drug List)
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug line indicates 'PA' before dispensing or billing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~120+drug line items
    statewideapplicability
    multipleQuantity Limits (QL)
    severalPrior Authorization (PA) / Specialty (SP)
    30/90supply options

    Formulary Coverage & Controls

    General pharmacy coverage criteria

    Covered when ALL of the following are met:

    Formulary inclusion: The drug is listed on the BCBSOK drug list for the member's benefit plan.

    Drugs not on the list are not covered unless an exception is granted.

    Benefit-specific tier and exclusions: Member coverage depends on the drug's tier and the member's specific benefit plan; some drug categories (e.g., erectile dysfunction, weight loss) may be excluded by certain plans.

    Refer to the member's benefit materials or call the number on the ID card for plan-specific coverage.

    Compliance with Special Requirements: Any Special Requirements indicated on the drug list (e.g., PA, ST, QL, DL, AC, SP) must be satisfied for coverage.

    PA must be approved prior to coverage; ST indicates required trial of alternative therapy; QL/DL restrict quantities; AC indicates ACA preventive rules may apply.

    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyPharmacy drug list and coverage rules (Drug List)
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug line indicates 'PA' before dispensing or billing.
    SourceLink
    On This Page
    Formulary Coverage & ControlsCodes, Product Lists & Supply RulesPrescriber Responsibilities & Authorization ProcessStep Therapy Flags & NotesPer-Product Dispensing LimitsWhere Drugs Are Covered (Medical vs Pharmacy/Specialty)Key Terms & AcronymsExamples of Authorization Triggers for InitiationPolicy Background

    Formulary coverage stance

    Formulary listing with tier and requirements/limits

    Formulary entries: Coverage stance is determined by the drug's placement on the formulary: each line lists Drug Tier and any Requirements/Limits (examples include PA, QL, SP).

    Specific clinical criteria for each PA/QL are provided elsewhere or via the PA process; the formulary line indicates which controls apply.

    Coverage controls

    Products are subject to coverage controls when Requirements/Limits codes are present

    Authorization and limits apply: When a drug line includes Requirements/Limits codes (e.g., AC, PA, QL, SP, NP, P), coverage requires compliance with those controls as specified by the plan and utilization management procedures.

    Detailed clinical authorization criteria are implemented through prior authorization or specialty program processes referenced on the drug list.

    Formulary coverage with PA/QL/SP

    Covered when formulary conditions met

    Formulary coverage conditions: A listed drug with Drug Tier and Requirements/Limits (PA, QL, SP) is covered only when the indicated requirements are met for the specific strength/pack.

    For oncology and specialty agents many entries include PA, QL, and SP; follow the PA documentation process and quantity limits shown on the formulary line.

    Formulary utilization controls (per drug)

    Coverage and utilization limits apply per listed drug formulation as shown below

    Example entry: If a drug entry lists 'Requirements/Limits = PA, QL (X per Y days), SP' then coverage requires prior authorization, is limited to the specified quantity over the specified time period, and may require specialty pharmacy processing.

    Apply these controls to each specific formulation and pack listed on the drug line.

    Formulary listing with utilization controls

    Coverage entries are listed per product with drug tier and any Requirements/Limits; where 'PA' or 'AC' or 'QL' appear they indicate conditions for coverage or utilization management.

    Formulary line coverage: Each drug entry includes a Drug Tier and may include Requirements/Limits (examples: AC, PA, QL, SP). Coverage depends on meeting those listed requirements.

    For contraceptives AC and specific QL values (e.g., 28 tablets/21 days or 1 ring/21 days) are used; for antidiabetic and GLP-1 agents PA and pen/pen-count QLs are specified per line.

    Formulary entries and per-drug limits

    Coverage entries list drug name, form/strength, formulary tier, and any Requirements/Limits

    Insulin products with quantity limit: Multiple insulin products (e.g., HUMULIN N, NOVOLIN N, NOVOLOG MIX, INSULIN GLARGINE-YFGN, TOUJEO, TRESIBA) are listed with 'Requirements/Limits = QL (100 mls/30 days)'.QL 100 mls/30 days

    Quantity limit applied per 30 days; prior authorization may be required for exceptions

    PA / SP / QL for specialty endocrine drugs

    Select high-cost endocrine and metabolic agents require additional controls

    Agents requiring PA and/or SP: Drugs such as ACTHAR, GALAFOLD, GENOTROPIN, MYALEPT, PALYNZIQ, RAVICTI, SKYTROFA, SOMAVERT, STRENSIQ and others are marked with Requirements/Limits indicating PA, SP, and/or QL.varies by drug

    Refer to the individual formulary line and PA program for specific prior authorization clinical criteria and quantity limits.

    Formulary requirements (partial)

    Coverage and utilization controls for listed drugs

    Specialty drugs with PA and QL: Certain specialty products (examples include teriparatide (Forteo), TRYNGOLZA, TYMLOS, VOXZOGO, YORVIPATH) are listed with PA and product-specific quantity limits (e.g., 1 device/28 days; 2.24 mls/28 days; 2 pens/28 days).see QL values in document

    These entries typically also carry SP designation; follow PA and specialty pharmacy processes for authorization and dispensing.

    General coverage with PA/QL where noted

    Coverage for listed drugs as indicated by Drug Tier with specified Requirements/Limits

    General formulary entries: Each drug line shows a Drug Tier and may include Requirements/Limits (PA, QL, SP). Coverage is contingent on meeting any listed PA or QL requirements.

    Examples include PA + QL for FUROSCIX, NEXLETOL/NEXLIZET, REPATHA and PA/QL/SP for many PAH or specialty cardiovascular agents.

    Product-level formulary coverage indicators

    Coverage and requirements are indicated per product as listed; many entries include Drug Tier and Requirements/Limits

    Product entry: Each named product line includes a Drug Tier and an optional Requirements/Limits field (examples: 'PA', 'QL', 'SP'). Coverage and dispensing follow those flags as shown for each formulation.

    Quantity limits for inhalers/nebulizers and specialty injectables are specified per product (e.g., QL inhaler/30 days; QL (3 inhalers/30 days); QL (60 blisters/30 days)).

    Formulary coverage stance (partial)

    Coverage follows formulary tier with listed requirements

    Formulary entry conditions: Drug coverage is subject to the formulary tier assignment and any listed requirements: Quantity Limits (QL), Prior Authorization (PA), Step Therapy (ST), Specialty (SP).

    When Requirements/Limits are present, providers must follow the plan's PA, ST or specialty pharmacy processes; absent explicit PA clinical criteria in this excerpt, follow payer submission instructions.

    Drugs not listed on the BCBSOK drug list, compounded preparations, repackaged products, and medications that have not received FDA approval are generally not covered. Members and prescribers should confirm plan-specific coverage and any exclusions by referring to the member's benefit materials or calling the number on the ID card. In addition, some benefit plans limit supply duration to a 30‑day supply with certain maintenance medications eligible for up to a 90‑day supply per plan terms.

    Within the formulary lists shown in this document there are no explicit per‑drug “not covered” statements in these chunks; instead coverage is represented by drug line items with Drug Tier and any Special Requirements. Absence of a drug from the list should be treated as not covered unless a Drug List exception is granted.

    Many entries use administrative shorthand in the Requirements/Limits column (e.g., PA, QL, SP, AC) to indicate utilization controls. These flags are administrative controls that require provider action (for example, prior authorization when PA is shown or adherence to a specified quantity when QL appears).

    The excerpted formulary lines do not list additional explicit exclusion language for specific products in this segment; coverage stance is presented as tier assignment and any Special Requirements on each line.

    This segment does not include discrete clinical exclusion statements; entries primarily display drug tiers and administrative requirement codes (e.g., quantity limits and prior authorization).

    No medical‑necessity exclusions are stated in these chunks; rather, many specialty oncology entries are shown with administrative controls such as PA, QL and SP where applicable.

    The provided product lines do not include explicit product‑level exclusions; instead, coverage is indicated by Drug Tier and any associated Special Requirements for each formulation.

    Formulary entries list drug name, strength/pack and Drug Tier, and where present the Special Requirements field specifies utilization controls such as PA and QL (for example, weight‑management agents such as WEGOVY show PA and QL (8 pens/180 days)).

    No explicit exclusions are stated in this excerpt; the list displays tiers and any Special Requirements for each drug line rather than explicit statements of noncoverage.

    These chunks do not enumerate explicit exclusions; entries for insulin products and others are shown with a common administrative control — e.g., many insulin formulations list a QL (100 mls/30 days) but are not shown as excluded.

    The document sections emphasize drug tiering and utilization management (quantity limits and prior authorization) rather than clinical exclusion criteria in the excerpted lines.

    No clinical exclusion criteria are stated in these oncology‑focused chunks; instead the entries show that many agents are managed administratively (e.g., PA, QL, SP where applicable).

    Non‑FDA‑approved drugs and repackaged versions of marketed medications are not covered under the benefit. Providers and members should consult plan materials or call the number on the ID card to confirm coverage for compounded, repackaged, or non‑FDA‑approved products.

    There are no explicit statements in these chunks designating drugs as “Not Medically Necessary” (NMN). Coverage presentation is via formulary line items with tier and Special Requirements rather than NMN labels in this excerpt.

    Within the provided excerpts, no products are explicitly labeled as Not Medically Necessary; the document uses administrative flags and tiering to convey coverage conditions.

    This segment does not contain explicit NMN determinations; oncology and specialty drugs are shown with utilization controls (PA, QL, SP) rather than NMN statements in these chunks.

    No NMN conditions are stated for the drug entries in this part of the document; entries instead list requirement codes that indicate authorization or quantity controls where needed.

    These chunks do not include NMN determinations; contraceptive and related product lines are shown with administrative codes such as AC and QL rather than NMN language.

    No medications are explicitly labeled as Not Medically Necessary in the insulin and related product listings shown here; quantity limits are the primary utilization control indicated.

    This segment contains no explicit NMN determinations; some high‑cost products show PA and QL (and sometimes SP) but not NMN labels in the excerpt.

    No NMN determinations are present in this part of the formulary excerpt; product coverage is detailed by tier and any Special Requirements without explicit NMN language.

    These chunks do not contain statements that any listed product is Not Medically Necessary; instead the excerpt uses tiering and requirement flags (PA, QL, SP) to indicate coverage controls.

    No NMN statements appear in the behavioral‑health and related drug lines shown here; formulary information is provided as Drug Tier plus Requirements/Limits entries (for example, quantity limits and occasional step therapy flags).

    Codes, Product Lists & Supply Rules

    Formulary notations and special requirement codesmixed
    PAPrior Authorization (notation in Special Requirements column)
    STStep Therapy (notation in Special Requirements column)
    QLQuantity Limits (notation in Special Requirements column)
    DLDispensing Limits (notation in Special Requirements column)
    ACAACA Preventive (notation in Special Requirements column)
    SPSpecialty (notation in Special Requirements column)
    Formulary requirement codes and limitsmixed
    QL (60 tablets/180 days)Quantity limit example for azithromycin tablets
    QL (28 tablets/30 days)Quantity limit example for clarithromycin ER 500 mg
    QL (120 capsules/30 days)Quantity limit example for itraconazole capsules
    PAPrior authorization required (not a billing code)
    SPSpecial Program (designation)
    Selected drug entries (examples)NDC_like_text
    FUZEON enfuvirtide for inj 90 mgDrug line item with Drug Tier = NP and QL 1 kit/30 days
    GENVOYA elvitegrav-cobic-emtricitab-tenofov af tab 150-150-200-10 mgDrug Tier = P; QL (30 tablets/30 days)
    HARVONI ledipasvir-sofosbuvir tab 45-200 mg, 90-400 mgDrug Tier = P; Requirements/Limits = PA, QL (30 tablets/30 days), SP
    VaccinesNDC_like_text
    COMIRNATY 2025-26 covid-19 mrna vac tris-pfizer im susp syr 30 mcg/0.3mlDrug Tier = P; Requirements/Limits = AC
    GARDASIL 9 human papillomavirus (hpv) 9-valent recomb vac suspDrug Tier = P; Requirements/Limits = AC
    Listed vaccine and biological productsmixed
    GARDASIL 9human papillomavirus (hpv) 9-valent recomb vac im susp
    HAVRIXhepatitis a vaccine susp prefilled syr / inj susp
    HEPLISAV-Bhepatitis b vaccine recomb adjuvanted pref syr
    HIBERIXhaemophilus b polysaccharide conjugate vac for inj 10 mcg
    IMOVAX RABIESrabies virus vaccine, hdc for inj susp
    IPOLINACTIVATED IPV poliovirus vaccine, ipv injection
    JYNNEOSsmallpox & monkeypox vac, live, non-replicating inj 0.5 ml
    M-M-RIImeasles-mumps-rubella virus vaccines for inj soln
    MENQUADFI / MENVEOmeningococcal (a, C, Y, and W-135) tetanus conjugate / oligo conj vac
    MNEXSPIKE / MODERNA / SPIKEVAXCOVID-19 mRNA vaccines (Moderna formulations)
    1–10 of 15
    1/2
    Selected specialty / antineoplastic agentsmixed
    abiraterone acetate (Zytiga)250 mg, 500 mg
    alectinib (ALECENSA)150 mg cap
    brigatinib (ALUNBRIG)30 mg, 90 mg, 180 mg
    niraparib + abiraterone (AKEEGA)combination tablets 50-500 mg, 100-500 mg
    palbociclib (IBRANCE)cap/tablet 75 mg, 100 mg, 125 mg
    duvelisib (COPIKTRA)cap 15 mg; 25 mg
    bosutinib (BOSULIF)caps/tab 50 mg, 100 mg, 400 mg, 500 mg
    cabozantinib (CABOMETYX / COMETRIQ)tabs/cap various strengths
    Partial drug entries from chunk 72mixed
    GAVRETOpralsetinib cap 100 mg
    gefetinibtab 250 mg (Iressa)
    GILOTRIFafatinib dimaleate tab 20 mg, 30 mg, 40 mg
    GLEOSTINElomustine cap 10 mg, 40 mg, 100 mg
    GOMEKLImirdametinib tab/cap (various strengths)
    HYCAMTINtopotecan hcl cap 0.25 mg, 1 mg
    hydroxyureacap 500 mg (Hydrea)
    Partial drug entries from chunks 73-74mixed
    IBRANCEpalbociclib cap/tab 75 mg, 100 mg, 125 mg
    IBTROZItaletrectinib adipate cap 200 mg
    ICLUSIGponatinib hcl tab 10 mg, 15 mg
    IDHIFAenasidenib mesylate tab 50 mg, 100 mg
    imatinibmesylate tab 100 mg, 400 mg (Gleevec)
    IMBRUVICAibrutinib various forms and strengths
    Additional drug entries from chunks 75-91mixed
    INLYTAaxitinib tab (various mg)
    INQOVIdecitabine-cedazuridine tab 35-100 mg
    JAKAFIruxolitinib phosphate tab 5 mg, 10 mg
    KISQALIribociclib succinate tab packs (200 mg, 400 mg, 600 mg)
    KOSELUGOselumetinib sulfate cap 10 mg, 25 mg
    LENVIMAlenvatinib cap therapy packs (4-24 mg daily dose variants)
    LYNPARZAolaparib tab 100 mg, 150 mg
    LONSURFtrifluridine-tipiracil tab (multiple strengths)
    LORBRENAlorlatinib tab 25 mg, 100 mg
    LUMAKRASsotorasib tab 120 mg, 240 mg, 320 mg
    1–10 of 17
    1/2
    Formulary drug entries in segmentNDC|mixed
    TIBSOVO ivosidenib tab 250 mgDrug formulary entry with Requirements/Limits = PA QL (60 tablets/30 days), SP
    TRUQAP capivasertib tab therapy pack 160 mg,200 mgRequirements/Limits = PA, QL (64 tablets/28 days), SP
    TUKYSA tucatinib tab 50 mgRequirements/Limits = PA, QL (300 tablets/30 days), SP
    VENCLEXTA venetoclax tab 10 mgRequirements/Limits = PA, QL (60 tablets/30 days), SP
    VITRAKVI larotrectinib sulfate oral soln 20 mg/mlRequirements/Limits = PA QL (300 mls/30 days), SP
    XALKORI crizotinib cap 200 mgRequirements/Limits = QL (60 capsules/30 days), SP
    Hormone/estrogen product entriesmixed
    ALORA estradiol td patch twice weekly 0.025 mg/24hrRequirements/Limits = QL (30 patches/30 days)
    RAYOS prednisone tab delayed releaseRequirements/Limits = QL (30 tablets/30 days)
    Contraceptive brand entries (sample)mixed
    NUVARINGetonogestrel-ethinyl estradiol va ring 0.12-0.015 mg/24hr
    OPILLnorgestrel tab 0.075 mg
    SLYNDdrospirenone tab 4 mg
    Antidiabetic and GLP-1/SGLT2 entries (sample)mixed
    FARXIGAdapagliflozin propanediol tab 5 mg, 10 mg
    GLYXAMBIempagliflozin-linagliptin tab 10-5 mg, 25-5 mg
    JANUMETsitagliptin phosphate-metformin hcl tab 50-500 mg, 50-1000 mg
    JANUMET XRsitagliptin phosphate-metformin hcl tab er 24hr (various strengths)
    JANUVIAsitagliptin phosphate tab 25 mg, 50 mg, 100 mg
    JARDIANCEempagliflozin tab 10 mg, 25 mg
    MOUNJAROtirzepatide soln auto-injector (various strengths)
    OZEMPICsemaglutide soln pen-inj (various concentrations)
    TRULICITYdulaglutide soln auto-injector 0.75 mg/0.5 mL
    RYBELSUSsemaglutide tab 3 mg, 7 mg, 14 mg
    Insulin product entries (sample)mixed
    FIASPinsulin aspart (with niacinamide) inj 100 units/mL
    HUMALOGinsulin lispro formulations (cartridge/pen/inj) 100 units/mL
    LYUMJEVinsulin lispro-aabc inj 100 units/mL
    NOVOLOGinsulin aspart inj 100 units/mL and pen/cartridge forms
    HUMULIN Rinsulin regular (human) inj 100 units/mL
    HUMULIN R U-500insulin regular (human) inj 500 units/mL
    N/A — no CPT/HCPCS/ICD-10/NDC codes in this excerptmixed
    No codes listed
    NDC/CPT/HCPCS not listedmixed
    No codes listed
    Formulary drug line-items (sample)mixed
    Tribenzorolmesartan-amlodipine-hydrochlorothiazide tab (various strengths)
    Perindopril erbumineperindopril erbumine tabs (2 mg, 4 mg, 8 mg)
    Dibenzylinephenoxybenzamine hcl 10 mg cap
    Minipressprazosin hcl cap (various strengths)
    Accuprilquinapril hcl tab (5,10,20,40 mg)
    Diuretics and fluid agentsmixed
    FUROSCIXfurosemide subcutaneous cartridge kit 80 mg/10 mL
    Lasixfurosemide tab (20,40,80 mg)
    chlorthalidonechlorthalidone tab (25 mg; 50 mg)
    Aldactonespironolactone tab (25,50,100 mg)
    Antihyperlipidemics / PCSK9 / new agentsmixed
    atorvastatinatorvastatin calcium tab (10,20,40,80 mg)
    Repathaevolocumab subcutaneous soln prefilled syringe 140 mg/ml
    NEXLETOLbempedoic acid 180 mg tab
    Cardiovascular specialty and PAH agentsmixed
    CAMZYOSmavacamten cap (various strengths)
    ENTRESTOsacubitril-valsartan (sprinkle) and tab formulations
    ORENITRAMtreprostinil diolamine ER tab (various strengths)
    Specialty cardiovascular / rare disease agentsmixed
    UPTRAVIselexipag tablets (various strengths) and titration packs
    VYNDAQELtafamidis meglumine (cardiac) cap 20 mg
    CAMZYOS (additional strengths)mavacamten cap 5 mg
    Erectile dysfunction agentsmixed
    Avanafil (Stendra)avanafil tab 50,100,200 mg
    Viagrasildenafil citrate tab 25,50,100 mg
    Cialistadalafil tab various strengths
    Antihistamines, promethazine, nasal steroid agentsmixed
    desloratadinedesloratadine formulations including ODT and combination products
    promethazinepromethazine HCl oral solution, suppositories, syrup
    fluticasone / mometasone / beclomethasoneintranasal steroid sprays (various products)
    No CPT/HCPCS/ICD-10 codes listed in these chunksmixed
    No codes listed
    Formulary requirement codes and limitsmixed
    QL (60 capsules/30 days)Quantity limit example applied to esomeprazole magnesium cap
    PAPrior Authorization requirement noted for some products (e.g., glycopyrrolate oral soln Cuvposa)
    Product-specific PA/QL/SP entriesmixed
    PA, QL (2 pens/28 days) , SPENTYVIO PEN vedolizumab auto-injector requirements/limits
    PA, QL (2 pens/28 days) , SPOMVOH mirikizumab-mrkz auto-injector requirements/limits
    Listed drugs and formulations (no procedural or billing codes in this segment)mixed
    No codes listed
    Formulary drug entries (partial)mixed
    risperidone tab 0.5 mg; 2 mg; 4 mgRisperdal — Drug Tier and QL specified
    VERSACLOZ clozapine susp 50 mg/mlQL (540 mls/30 days), ST
    VRAYLAR cariprazine hcl cap 1.5 mg; 3 mg; 4.5 mg; 6 mgQL (30 capsules/30 days)
    Weight management and stimulant agentsmixed
    liraglutide (weight mngmt) soln pen-inj 18 mg/3ml (Saxenda)PA, QL (15 mls/30 days)
    phentermine hcl cap 15 mg; 30 mgQL (30 capsules/30 days)
    phentermine hcl-topiramate cap er (Qsymia)PA, QL (30 capsules/30 days)
    Selected neurology and MS agentsmixed
    INGREZZA valbenazine tosylate cap 40 mgQL (28 capsules/180 days), SP, PA noted
    MAVENCLAD cladribine tab therapy pack 10 mgPA, QL (various per pack), SP
    NDC/Codes not listed in this segmentmixed
    No codes listed
    Supply limits
    Typical supplyUp to 30-day supply for most prescriptions; some plans allow up to 90-day supply for maintenance medications
    Maintenance medicationsMay be eligible for 90-day supply (e.g., chronic BP, diabetes, cholesterol therapies)
    Controlled substances noteState laws may restrict coverage if dispensed beyond dispensing limits; member may be responsible for full cost if limit exceeded
    ExceptionsDrug List exceptions or PA requests submitted to number on member ID; see plan materials for details
    Example quantity limits
    Azithromycin (tablets)QL 60 tablets per 180 days
    Clarithromycin ER 500 mgQL 28 tablets per 30 days
    Itraconazole capsulesQL 120 capsules per 30 days
    Quantity Limits
    Lopinavir-ritonavir (Kaletra)QL 180 tablets/90 days or QL 120 tablets/30 days depending on strength/pack
    Maraviroc (Selzentry)QL 60 tablets/30 days (150 mg) or QL 120 tablets/30 days (300 mg)
    Paxlovid (nirmatrelvir + ritonavir)QL examples: 11 tablets/30 days; 20 tablets/90 days; 30 tablets/90 days depending on pack
    Quantity Limits examples
    Selected antineoplastics (examples)QL examples include 120 tablets/30 days; 240 capsules/30 days; 21 capsules/28 days; 56 capsules/28 days
    Abiraterone (Zytiga)PA + QL (120 tablets/30 days)
    Everolimus (Afinitor) formulationsPA + QL (30/60/90 tablets per 30 days depending on formulation)
    Quantity Limits examples
    GAVRETO (pralsetinib)QL 120 capsules/30 days
    LONSURF (trifluridine‑tipiracil)PA + QL 60 tablets/28 days (other pack sizes shown)
    ROZLYTREK (entrectinib) pellet packPA + QL 336 pellets/28 days
    Common quantity limits
    Common oral/tablet limitsExamples include QL 60 tablets/30 days; QL 64 tablets/28 days; QL 300 tablets/30 days
    Liquid/suspension limitsExamples include QL 300 mL/30 days; QL 540 mL/30 days for select suspensions
    Inhaler/neb limitsExamples include QL (3 inhalers/30 days), QL (60 blisters/30 days)
    Common insulin quantity limit
    Insulin common QLQL 100 mLs per 30 days for many insulin products (e.g., FIASP, HUMALOG, NOVOLOG, HUMULIN)
    Pen/cartridge formsPen and cartridge formulations are subject to same 100 mL/30-day QL (noted per product)
    Exceptions/variationsSome specialty insulin presentations may list specific pack/pen counts—refer to line-item entry
    Oral contraceptive dispensing quantity
    Combined oral contraceptivesQL 28 tablets per 21 days (typical for many combined oral contraceptives); access code (AC) often noted
    NuvaRing (vaginal ring)QL 1 ring per 21 days
    Transdermal patch (e.g., TWIRLA)QL examples: 3 patches per 21 days or QL 30 patches/30 days for some patch products

    Prescriber Responsibilities & Authorization Process

    Prior Authorization

    Obtain prior authorization when indicated

    Obtain prior authorization when the drug line shows 'PA' in the Requirements/Limits column; approval must be received before the medication may be covered under the plan.

    • PA flag appears on formulary lines to indicate prior authorization is commonly required.
    Prior Authorization

    Follow PA and specialty program requirements

    For select specialty or high‑cost anti‑infective and antiviral agents follow PA and any Special Program (SP) requirements noted on the formulary line prior to dispensing.

    • Examples in the list (e.g., HARVONI, tobramycin nebu) show PA and SP designations that must be satisfied.
    Prior Authorization

    PA required for select antivirals and specialty drugs

    Prescribers must request prior authorization for antiviral and other specialty medications flagged with 'PA' on the drug list; these entries may also carry QL or SP designations.

    • Examples include PAXLOVID and PEGASYS which list PA and/or QL and SP on the formulary lines.
    Prior Authorization

    PA required for many oncology agents

    Prior authorization is required for many antineoplastic and other oncology agents when 'PA' (often with QL and SP) appears in Requirements/Limits; obtain authorization before coverage.

    • Multiple oncology entries (e.g., abiraterone, ALECENSA) list PA, QL and SP that must be met.
    Prior Authorization

    PA for listed oncology products

    Obtain prior authorization for listed oncology drugs when Requirements/Limits includes 'PA' — each strength/pack may require its own authorization.

    • Several oral oncology entries (e.g., GAVRETO, GOMEKLI) show PA and QL per formulation.
    Prior Authorization

    Obtain PA where specified on the formulary line

    When a formulary line shows 'Requirements/Limits = PA' the provider must secure prior authorization before the plan will cover the specified product/formulation.

    • This applies to individual drug formulations where PA is stated (examples: TIBSOVO, VENCLEXTA, XPOVIO).
    Prior Authorization

    PA required for select antidiabetics/GLP‑1 agents

    Certain antidiabetic and GLP‑1 agents (e.g., MOUNJARO, OZEMPIC, TRULICITY) are designated 'PA' and often include quantity limits — submit PA requests and supporting documentation as required.

    • MOUNJARO: Requirements/Limits = PA, QL (4 pens/180 days or 4 pens/28 days depending on strength).
    • OZEMPIC: Requirements/Limits include PA and QL per pen strength.
    Prior Authorization

    PA for specialty endocrine/metabolic drugs

    Prior authorization is required for select specialty endocrine/metabolic agents that show 'PA' and often 'SP' on the formulary; secure PA and follow specialty handling as indicated.

    • Examples include ACTHAR and GENOTROPIN with Requirements/Limits = PA, SP.
    Prior Authorization

    PA required for listed specialty agents

    For specialty agents listed with 'PA' (and often 'SP') obtain prior authorization before dispensing; follow any quantity limits shown on the drug line.

    • Examples: Forteo (teriparatide) lists PA and QL (2.24 mls/28 days); TRYNGOLZA lists PA and QL (1 device/28 days).
    Prior Authorization

    PA and QL for FUROSCIX

    FUROSCIX requires prior authorization and is limited to QL 8 kits per 180 days; failure to obtain PA or exceeding the QL may result in denial.

    • FUROSCIX formulary line: Requirements/Limits = PA, QL (8 kits/180 days).
    Prior Authorization

    PA and QL for select lipid and biologic agents

    Obtain prior authorization and adhere to the listed quantity limits for select lipid‑modifying and specialty biologic agents (e.g., NEXLETOL/NEXLIZET: PA, QL 30 tablets/30 days; REPATHA: PA, QL 6 syringes/28 days).

    • Follow PA + QL as stated on each product line prior to coverage.
    Prior Authorization

    PA + QL + SP for PAH and specialty cardiovascular agents

    Many pulmonary arterial hypertension and specialty cardiovascular agents require prior authorization and often include quantity limits and specialty designation; obtain PA and comply with QL/SP as shown.

    • Examples: ADEMPAS (PA, QL 90 tablets/30 days), UPTRAVI (PA, QL 60 tablets/30 days), OPSUMIT/ORENITRAM entries show PA, QL, SP.
    Prior Authorization

    Obtain PA when product lists 'PA'

    When a product is marked 'PA' on the formulary (for example XHANCE) the provider must obtain prior authorization before the plan will cover the medication.

    • Check the Requirements/Limits field on the drug line for PA status.
    Prior Authorization

    Specialty biologics require PA and SP handling

    Specialty biologics and cystic fibrosis modulators marked with 'PA' or 'PA, SP' require prior authorization and specialty pharmacy handling; submit PA and arrange specialty routing as required.

    • Examples include FASENRA, NUCALA, XOLAIR, TRIKAFTA which list PA and SP on their formulary lines.
    Prior Authorization

    PA required for specified high‑cost products

    Obtain prior authorization for the products identified with 'PA' on the formulary; many high‑cost agents list PA as a coverage requirement.

    • PA is indicated for numerous specialty biologics and high‑cost drugs in this segment.
    Prior Authorization

    Secure prior authorization when listed

    When a drug line shows 'PA' you must secure prior authorization before the plan will cover the medication; follow the Requirements/Limits on the formulary entry.

    • Examples include PROCYSBI and tasimelteon entries showing PA (and sometimes SP/QL).
    Prior Authorization

    PA required for listed specialty and biologic drugs

    Prior authorization is required for many listed specialty and biologic drugs (e.g., PLEGRIDY, ZEPOSIA, adalimumab products, ENBREL, HUMIRA); obtain PA and comply with any QL/SP noted on the drug line.

    • These entries commonly include PA, QL and SP flags that must be satisfied for coverage.
    Step Therapy

    Step therapy may be required (ST)

    When a drug line includes 'ST' the benefit may require step therapy — try the required cost‑effective alternative first per the plan before coverage for the requested agent is available.

    • Step Therapy (ST) is noted next to medications where the program commonly applies.
    Note

    Step therapy sequences not specified here

    The formulary listing in these excerpts does not provide explicit step therapy sequences for most agents; check the benefit materials or plan resources for specific ST algorithms.

    • Only flags (PA, QL, SP, ST) are shown; full step details may be maintained separately.
    Documentation Required

    Submit PA/exception requests to the number on the member ID card

    Providers must submit PA or exception requests to the phone number on the member ID card; standard decisions are provided within 15 calendar days and expedited requests within 72 hours.

    • Use the member ID card contact for PA/submission and timing inquiries.
    Note

    Specialty (SP) designation may trigger program requirements

    Products labeled with SP may be managed through specialty pharmacy pathways and could require enrollment in a specialty program; follow PA/SP routing indicated on the formulary line.

    • SP designation (e.g., PALFORZIA levels) signals specialty program management.
    Note

    No explicit step therapy details on these lines — confirm plan rules

    Where no explicit step therapy rules are provided on the formulary lines, providers should still check plan materials — many entries only show PA, QL, SP or AC flags without step sequences.

    • Absence of ST on a line does not guarantee the plan has no step requirements elsewhere.
    Documentation Required

    Follow access (AC) indicators for applicable products

    Some formulary lines include access or administrative codes (AC) for contraceptives or related agents; follow the payer's access criteria and submission processes where AC is shown.

    • Examples: multiple contraceptive entries list AC and QL (28 tablets/21 days).
    Note

    When ST not shown, confirm PA/QL still apply

    Where step therapy is not specified in the excerpt, providers should assume PA and QL requirements listed on the drug line still apply and confirm any step requirements via plan resources.

    • Many agents show PA and QL even when ST is not listed (e.g., MOUNJARO entries).
    Step Therapy

    Follow ST or SP pathways when flagged

    Products flagged with 'ST' or 'SP' (e.g., KERENDIA) may indicate step‑therapy or specialty pharmacy pathways; obtain authorization and follow pathway requirements where present.

    • KERENDIA lists QL (30 tablets/30 days) and ST — follow the ST requirement if present on the member's plan.
    Step Therapy

    ST applies to select CNS and psychiatric agents

    Certain formulary entries note step therapy for specific CNS and related drugs (examples include AUVELITY, FETZIMA, FLUOXETINE DR and clozapine ODT) — follow ST requirements prior to coverage of the requested agent.

    • Check the Requirements/Limits field for 'ST' and the member's benefit for required prior agents.
    Documentation Required

    Document prior therapy for ST when requesting PA

    When step therapy is noted for agents (ST), try the specified proven, cost‑effective medication first per the program; documentation of prior therapy may be required with PA.

    • ST flags indicate the member may need to fail or be intolerant to the step medication before authorization is granted.
    Note

    Confirm step therapy via plan resources when not listed

    If no step therapy is documented in the excerpt for a product, verify benefit‑specific step requirements with the plan; many formulary lines only display PA/QL/SP codes without full ST detail.

    • The formulary often lists PA/QL/SP but not the failure criteria or step sequence.
    Note

    Specialty designation may require specialty pharmacy routing

    SP designation on a formulary line may require routing through a specialty pharmacy and could trigger additional PA or program steps — coordinate with the plan's specialty pharmacy processes.

    • Examples: multiple high‑cost agents marked SP are managed through specialty channels.
    Step Therapy

    Execute step therapy when 'ST' is shown

    Step therapy is indicated for certain products using the 'ST' flag; when present, providers must follow the specified step requirements before the requested drug will be covered.

    • Examples of ST‑flagged products include AUVELITY, FETZIMA, FLUOXETINE DR, CLOZAPINE ODT and others.
    Step Therapy

    Examples of products with ST noted

    Examples of step therapy noted on the formulary include AUVELITY, FETZIMA, FLUOXETINE DR, RISPERIDONE ODT and CLOZAPINE ODT; follow the ST requirement before seeking coverage for the requested agent.

    • Check the Requirements/Limits field for 'ST' on the specific line item.
    Step Therapy

    ST noted for select agents (examples)

    Step therapy is noted for select agents (e.g., VERSACLOZ clozapine suspension, gabapentin formulations) — providers must follow the ST pathway where indicated.

    • VERSACLOZ lists QL (540 mls/30 days) and ST on the formulary line.
    Note

    No ST algorithm in this excerpt — confirm with plan

    When no explicit step therapy algorithm is provided on a formulary segment, rely on the PA, QL and SP flags shown and confirm step requirements through the plan's clinical criteria or provider resources.

    • Many entries only display administrative flags; full step criteria may be available via plan tools.
    Documentation Required

    Provide clinical documentation to support PA

    Submit documentation to support prior authorization requests when the drug line lists 'PA'; the PA request should include clinical rationale and any required prior‑therapy or diagnosis information.

    • Examples: oncology drugs listed with PA will require supporting documentation to meet the PA criteria.
    Billing Rule

    Adhere to documented quantity limits (QL)

    Adhere to quantity limits indicated with 'QL' on each drug line; dispensing quantities that exceed the listed QL will likely require additional documentation or prior authorization.

    • Examples include azithromycin QL (60 tablets/180 days) and itraconazole QL (120 capsules/30 days).
    Billing Rule

    Do not exceed QL without authorization

    When a QL is specified for a product (e.g., many insulin and inhaler entries), dispense only up to the listed quantity unless PA is obtained; claims exceeding QL may be denied without authorization.

    • Insulin examples: QL (100 mls/30 days) is noted for multiple insulin products.
    Documentation Required

    Follow Requirements/Limits codes shown on drug lines

    Document and follow the Requirements/Limits codes (AC, PA, QL, SP, ST) shown on each formulary line; these designators indicate authorization, access, quantity, specialty routing, or step requirements that must be met for coverage.

    • AC = access/administrative control; PA = prior authorization; QL = quantity limit; SP = specialty; ST = step therapy.
    Documentation Required

    Submit supporting clinical evidence with PA requests

    Provide the clinical documentation required to meet PA when the entry lists 'PA' for a specific drug and strength; include any requested prior‑therapy history, diagnoses, or test results to support approval.

    • Examples: PA entries for VENCLEXTA and VITRAKVI imply submission of supporting clinical information.
    Documentation Required

    Document both clinical need and requested quantity for PA+QL entries

    When PA and QL are listed for a product, include documentation addressing both the clinical need and the requested quantity in the PA submission; failing to document appropriately may result in denial.

    • Examples: NEXLETOL/NEXLIZET and REPATHA list PA plus QL that must be satisfied.
    Denial Risk

    Lack of PA may result in denial

    Many formulary lines include PA — absence of required authorization may lead to claim denial; verify PA status on the drug line and obtain approval prior to dispensing.

    • Claims for drugs listed with 'PA' can be denied if PA is not obtained.
    Billing Rule

    Ensure dispensed NDC/form matches QL on formulary line

    Adhere to QL values tied to specific NDCs or product forms; claims that exceed the listed QL for the NDC/product form may be rejected during adjudication unless PA authorizes the excess.

    • Example: omeprazole cap delayed release shows QL (60 capsules/30 days).
    Documentation Required

    Follow specialty pharmacy PA documentation and routing

    For specialty drugs designated 'SP' and 'PA', follow the specialty drug PA documentation process and route the prescription through the specialty pharmacy as required on the formulary line.

    • Examples: AVONEX and other interferons list PA, QL and SP — submit PA and route through specialty pharmacy.
    Documentation Required

    Provide PA documentation for specialty drugs

    Prescribers must provide documentation to support PA requests for specialty agents (examples include TRYNGOLZA, TYMLOS, VOXZOGO); include clinical justification and quantity requested.

    • Many specialty products list PA and QL and will require documentation to meet PA criteria.
    Denial Risk

    Non‑formulary or non‑FDA drugs: risk of denial — request exception

    Coverage requests for non‑formulary, non‑FDA‑approved, repackaged or compounded medications may be denied; obtain an exception prior to dispensing if the drug is not on the list.

    • Repackaged medications and non‑FDA‑approved drugs are not covered per the policy.
    Denial Risk

    PA required for certain agents — risk of denial without PA

    Drugs shown with 'PA' on the formulary (e.g., ARIKAYCE, posaconazole, HARVONI) require prior authorization and could be denied if PA conditions are not met.

    • Check the Requirements/Limits field for PA and follow the PA process.
    Denial Risk

    PA+QL entries: obtain PA and adhere to quantity limits to avoid denial

    When a formulary line indicates PA and QL, failure to obtain authorization or exceeding the stated quantity may result in claim denial; secure PA and document necessity before dispensing.

    • FUROSCIX and NEXLETOL/NEXLIZET are examples where PA and QL apply and must be met.
    Denial Risk

    Confirm PA and SP for biologics to avoid denial

    Prior authorization is indicated for many biologics and specialty products; lack of PA or not following SP routing can lead to denied coverage — confirm PA/SP on the drug line before prescribing.

    • Adalimumab products and other biologics commonly list PA, QL and SP.
    Documentation Required

    Document prior therapy when ST applies

    If a product's Requirements/Limits include 'ST', the plan requires step therapy; document prior use of the required alternative(s) when submitting a PA or exception.

    • ST is applied to products such as FETZIMA, FLUOXETINE DR, AUVELITY and some clozapine formulations.
    Note

    Check and follow Requirements/Limits flags on each drug line

    Provider actions: check the formulary line for PA, QL, SP, ST or AC flags and follow the corresponding process (obtain PA, comply with QL, route to specialty pharmacy, follow step therapy or access criteria) before dispensing.

    • Use the drug list and member ID resources to confirm benefit‑specific requirements.
    Documentation Required

    Include full clinical support with PA submissions

    When PA is shown, include clinical documentation, prior‑therapy history, and quantity rationale with the PA request; incomplete documentation increases the risk of denial or delay.

    • Oncology and specialty agents commonly require supporting clinical information to satisfy PA.
    Billing Rule

    Dispense only up to the listed QL unless PA authorizes more

    For products with QL, dispense the quantity shown on the formulary line; if a larger quantity is clinically necessary, obtain PA to authorize the excess prior to dispensing.

    • Examples of QL values are provided inline (e.g., 60 tablets/180 days, 120 capsules/30 days).
    Prior Authorization

    PA+QL+SP entries: obtain PA, adhere to QL, and use specialty pharmacy

    Many specialty products list both PA and QL; providers must obtain PA and request the permitted quantity per the formulary line — routing through specialty pharmacy may also be required.

    • Examples: PLEGRIDY and OMVOH list PA, QL and SP on their entries.
    Prior Authorization

    PA indicated on formulary lines requires authorization before coverage

    When a formulary line shows 'PA' providers must obtain prior authorization before the medication will be covered — confirm this requirement on each drug/strength listed.

    • General rule across the formulary: 'PA' indicates authorization required prior to coverage.
    Documentation Required

    Request PA for the exact listed formulation/strength

    Prior authorization requests should reference the exact product, strength and pack shown on the formulary line; PA requirements can vary by formulation and NDC.

    • Many oral oncology and antiviral lines list PA per strength/pack — submit PA for the exact formulation.
    Prior Authorization

    FUROSCIX requires PA and QL adherence

    PA and QL are documented for FUROSCIX and exceeding the listed QL or dispensing without PA may result in claim denial; obtain PA and adhere to QL before dispensing.

    • FUROSCIX: Requirements/Limits = PA, QL (8 kits/180 days).
    Documentation Required

    Include requested quantity when submitting PA for PA+QL items

    When a product line lists 'PA, QL', include the quantity requested in the PA submission and reference the QL on the formulary; missing this can delay review or lead to denial.

    • Examples: REPATHA (PA, QL 6 syringes/28 days); ADEMPAS (PA, QL 90 tablets/30 days).
    Note

    Coordinate with specialty pharmacy when 'SP' is listed

    If a drug line includes 'SP', coordinate with the specialty pharmacy for dispensing and PA processes as specialty routing and program requirements may apply.

    • High‑cost endocrine and metabolic agents commonly have SP and PA flags that trigger specialty management.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Step Therapy Flags & Notes

    ItemNote
    ST is noted in the Special Requirements column when step therapy applies; the policy states medications with common ST requirements are generally marked with 'ST'.
    Refer to Step Therapy (ST) description: if ST commonly required it will be noted next to the medication with 'ST' under Special Requirements.
    Product / ExamplePA / QL / ST presence
    QL indicated (e.g., QL (60 tablets/180 days)); no explicit step sequences shown.
    Requirements/Limits = PA, QL (21 capsules/28 days), SP; step sequences not provided in document.
    Requirements/Limits = PA, QL (4 pens/180 days or 4 pens/28 days depending on strength); no ST sequence detailed.
    Product / DesignationSP / NP / Step therapy
    Requirements/Limits = SP for multiple PALFORZIA level packs (indicates specialty program). No step sequence provided.
    Entries show SP and PA designations (e.g., JYNARQUE Requirements/Limits = PA, QL, SP). Step therapy specifics not included.
    Listed with QL (30 tablets/30 days) and ST noted; SP/NP designations appear for other products but step sequences are not detailed.
    SummaryDetail
    The formulary shows tiering and Requirements/Limits (PA, QL, SP, ST flags) but does not present explicit step therapy sequences or ordered step algorithms within the listed chunks.
    Step Therapy (ST) is described as a program and when commonly required will be noted with 'ST' next to the medication; refer to benefit plan materials for specific step sequences.
    ContraceptiveAccess/AC indicator
    Many contraceptive lines show 'AC' in Requirements/Limits (e.g., AC plus QL (28 tablets/21 days)), indicating AC (access) administrative indicators on contraceptives.
    DEPO‑SUBQ PROVERA and other contraceptive formulations are listed with Requirements/Limits = AC (and QL where specified).
    FindingImplication
    Document contains many PA indicators for agents (e.g., IBRANCE PA, MOUNJARO PA) but does not provide explicit step-edit algorithms or failure criteria within these excerpts.
    When PA appears on a line, prior authorization must be obtained; step-specific edits are not provided in the listed segments.
    DrugST flag
    Listed with Requirements/Limits = QL (30 tablets/30 days) , ST — step‑therapy flag (ST) is explicitly shown for KERENDIA in the document.
    Specialty agent examplesStep therapy specified?
    Requirements/Limits = PA, QL (6 syringes/28 days) , SP — PA and SP indicated; no explicit ST sequence provided.
    Requirements/Limits = PA, QL (30 tablets/30 days) — PA/QL listed; step therapy not specified.
    Multiple adalimumab entries show PA, QL (2 pens/28 days), SP — step therapy details are not provided in these excerpts.
    ObservationEvidence from document
    The policy states step therapy flags (ST) may be noted, but the drug list excerpts do not include ordered step therapy sequences or failure requirements — only flags and other Requirements/Limits are shown.
    Refer to benefit plan materials or specific PA/step therapy program documents for full step sequence details.
    Oral antiemetic / therapy packManagement
    Aprepitant capsule therapy packs and oral suspension entries include QL entries (e.g., QL (3 packs/30 days) or QL (9 kits/30 days) for some formulations), indicating quantity limits and potential management controls.
    Doxylamine-pyridoxine entries show QL (60 or 120 tablets/30 days) — oral antiemetic therapy packs have QL and may be managed per QL settings.
    Product examplesST flag present
    Requirements/Limits = ST (document lists AUVELITY with 'ST').
    FETZIMA entries include Requirements/Limits = ST (e.g., FETZIMA TITRATION PACK).
    Requirements/Limits = QL (30 tablets/30 days) , ST — BELSOMRA is listed with ST flag.
    AgentStep therapy noted?
    Requirements/Limits = QL (540 mls/30 days) , ST — ST is noted for VERSACLOZ.
    Several CLOZAPINE formulations include QL and ST (e.g., CLOZAPINE ODT entries: QL and ST noted).
    Document cites that some gabapentin once-daily products note ST; specific entries referenced as examples of ST notation.
    Biologics / Specialty agentsPA and ST detail
    PA is frequently required prior to coverage for listed biologics (Requirements/Limits include 'PA' and often 'SP'); however, explicit step therapy sequences or step-specific clinical failure criteria are not provided in the excerpts.
    Obtain prior authorization where PA is indicated; step therapy specifics, if used, should be confirmed in the plan's step therapy program documentation since the drug list shows flags but not step algorithms.

    Per-Product Dispensing Limits

    Controlled substances / other medications (QL/DL)
    Requirements/Limits codesPA = Prior Authorization; QL = Quantity Limit; DL = Dispensing Limit; ST = Step Therapy; SP = Specialty; AC = ACA/Access Criteria
    Quantity/dispensing limitsDisplayed as e.g., 'QL (30 tablets/30 days)' or time‑based limits in the Special Requirements column
    Provider actionWhen QL/DL present, dispensing beyond the limit may require prior authorization or the member may be responsible for full cost
    Azithromycin tablets QL example
    Azithromycin tabletsQL 60 tablets per 180 days (example shown on formulary)
    Clinical noteQuantity limits documented on drug list; dispensing beyond QL may require PA or be member‑paid
    ReferenceSee MACROLIDES section for specific pack/strength entries and QL notation
    Clarithromycin ER 500 mg QL example
    Clarithromycin ER 500 mgQL 28 tablets per 30 days (listed as QL on formulary)
    Formulation noteExtended‑release clarithromycin entries show QL per 30‑day period
    ImplicationDispensing above QL will likely require additional documentation or PA
    Itraconazole capsules QL example
    Itraconazole capsules (Sporanox)QL 120 capsules per 30 days
    Oral solutionItraconazole oral solution has QL 1200 mLs per 30 days listed for some presentations
    Formulary placementListed under antifungals with QL specified for both capsule and solution forms
    ARIKAYCE QL
    ARIKAYCE (amikacin liposome inhalation)QL 235.2 mLs (line‑item quantity shown)
    FUZEON (enfuvirtide) inj 90 mgQL 1 kit per 30 days
    GENVOYA (combo tablet)QL 30 tablets per 30 days
    FUZEON QL
    FUZEON (enfuvirtide inj 90 mg)QL 1 kit per 30 days
    Tier/requirementListed as NP with QL on formulary line
    Provider notePA may also apply for some injectable antiretrovirals — check line‑item Requirements/Limits
    GENVOYA QL
    GENVOYA (elvitegravir-cobicistat-emtricitabine-tenofovir)QL 30 tablets per 30 days
    Formulary noteListed with QL on drug line — typical monthly tablet limit
    Special handlingSome antiretroviral combos may also carry SP designation
    MAVYRET QL
    MAVYRET (glecaprevir‑pibrentasvir)PA + QL 90 tablets per 30 days (other pack sizes shown)
    Hepatitis C therapyMultiple pack/strength entries with PA and QL noted on formulary
    Specialty designationOften managed as SP for treatment courses
    PREVYMIS QL
    PREVYMIS (letermovir) tabletsQL 200 tablets per 365 days
    Pack variationsPellet packs may have different QL/PA notations on the line item
    Use caseQL reflects typical prophylactic/therapeutic duration limits
    SUNLENCA QL
    SUNLENCA (lenacapavir) 300 mg tabQL 4 tablets per 365 days (therapy pack variations noted)
    Annual limitSmall tablet counts indicated per year for certain long‑acting agents
    Specialty handlingOften SP-managed; check Requirements/Limits for PA
    Selected specialty/antineoplastic examples
    Antineoplastic examplesQL examples include 120 tablets/30 days; 240 capsules/30 days; 56 capsules/28 days; 21 capsules/28 days
    PA and SPMany oral oncology agents are listed with PA + QL and SP designations
    Apply per formulationLimits are applied per strength/pack as shown on each line item
    GAVRETO QL
    GAVRETO (pralsetinib) cap 100 mgQL 120 capsules per 30 days
    Requirement codesListed as NP with QL and SP indicators on the formulary line
    Provider implicationPA may be required in addition to QL for specialty oncology agents
    LONSURF QL
    LONSURF (trifluridine‑tipiracil)PA + QL 60 tablets per 28 days (pack‑dependent variations noted)
    Titration/packsSome strengths/packs have different QL values (e.g., 80 tablets/28 days)
    SpecialtyTypically SP-managed with PA
    ROZLYTREK QL
    ROZLYTREK pellet pack 50 mgPA + QL 336 pellets per 28 days (pellet pack entry)
    Capsule formsOther capsule strengths show different QL (e.g., 30/90 capsules per 30 days)
    SP indicationOften managed as specialty (SP) with PA
    PIQRAY QL
    PIQRAY (alpelisib) 200 mg daily dosePA + QL 28 tablets per 28 days (daily‑dose pack examples)
    Pack dosingDaily dose packs list QL based on tablets required per dosing regimen
    Specialty handlingSP and PA common for these agents
    TIBSOVO QL
    TIBSOVO (ivosidenib) 250 mgPA + QL 60 tablets per 30 days
    TRUQAP (capivasertib)PA + QL 64 tablets per 28 days
    VITRAKVI (larotrectinib) oral solnPA + QL 300 mLs per 30 days (soln); capsule forms have capsule QLs
    TRUQAP QL
    TRUQAP (capivasertib) tab 200 mgPA + QL 64 tablets per 28 days
    TUKYSA (tucatinib)PA + QL 300 tablets per 30 days (50 mg pack) / 120 tablets per 30 days (150 mg pack)
    SP notationSpecialty (SP) designation appears on many entries with PA/QL
    VITRAKVI QL
    VITRAKVI oral soln 20 mg/mLPA + QL 300 mLs per 30 days
    Capsule formsCapsule QLs listed separately (e.g., 60/180 capsules per 30 days depending on strength)
    Provider notePA required when indicated; check line item for exact QL and SP status
    ALORA patch QL
    ALORA transdermal patchQL 30 patches per 30 days (example patch QL entry)
    Patch dosing frequencySome patches are dosed twice weekly or weekly—QL reflects pack counts per 30 days
    Formulary noteSee hormone/estrogen product entries for patch‑specific QLs
    Contraceptive QL examples
    Combined oral contraceptivesQL 28 tablets per 21 days is commonly listed; some products show AC (ACA) + QL
    Vaginal ring (NuvaRing)QL 1 ring per 21 days
    Transdermal patch (TWIRLA)QL 3 patches per 21 days (example); other patch products show 30 patches/30 days depending on product
    MOUNJARO/TRULICITY/OZEMPIC & insulins QL examples
    MOUNJARO (tirzepatide)PA + QL: 4 pens per 180 days (some strengths) or 4 pens/28 days depending on strength
    TRULICITY (dulaglutide)PA + QL 4 pens per 28 days
    OZEMPIC (semaglutide)PA + QL 1 pen/28 days or QL 3 mLs/28 days for certain concentrations
    GLYXAMBI / SYNJARDY / TRIJARDY XR QL examples
    GLYXAMBI / SYNJARDY / TRIJARDY XRQL examples: 30 or 60 tablets per 30 days depending on product and strength
    SYNJARDY XRQL 60 tablets per 30 days (example)
    TRIJARDY XRQL 30–60 tablets per 30 days depending on strength
    Multiple insulin products QL (100 mls)
    Multiple insulin products (sample)Common QL 100 mLs per 30 days across many HUMULIN, NOVOLIN, NOVOLOG MIX, INSULIN GLARGINE, TOUJEO, TRESIBA entries
    Pen/cartridge/prefill formsPen and cartridge formats list same 100 mL/30‑day QL where applicable
    Provider actionDispensing above QL may require PA or be member‑paid—see plan materials
    CRENESSITY capsules QL
    CRENESSITY (capsules)QL 60 capsules per 30 days
    CRENESSITY (oral solution)QL 120 mLs per 30 days
    ReferenceSeparate QL entries for capsule and oral solution forms on formulary
    CRENESSITY oral solution QL
    CRENESSITY (oral solution)QL 120 mLs per 30 days
    Capsule formCapsules have QL 60 capsules/30 days listed separately
    Formulary noteBoth formulations appear with distinct QLs on line items
    GALAFOLD QL
    GALAFOLD (migalastat)PA + QL 14 capsules per 28 days
    SP designationListed as SP in addition to PA/QL on formulary
    Provider implicationPA documentation required when indicated; adhere to QL
    FOLLISTIM AQ cartridges QL
    FOLLISTIM AQ cartridgesQL 15 cartridges per 30 days
    SP/PAOften managed through specialty channels; check Requirements/Limits for PA/SP
    Use caseCartridge QL reflects typical fertility treatment cycles
    SOMAVERT QL
    SOMAVERT (pegvisomant)PA + QL 30 vials per 30 days
    SP designationListed with SP on formulary line
    Clinical noteQL aligns with dosing/vial usage over monthly period
    Forteo QL
    Forteo (teriparatide) soln pen‑inj 560 mcg/2.24 mLPA + QL 2.24 mLs per 28 days
    SPListed as SP; PA required per line item
    Dispense implicationQL reflects one pen/device supply per 28‑day period
    TRYNGOLZA QL
    TRYNGOLZA (olezarsen) 80 mg/0.8 mLPA + QL 1 injection device per 28 days
    SPSpecialty designation noted on formulary line
    Provider actionPA documentation required when indicated; adhere to device QL
    TYMLOS QL
    TYMLOS (abaloparatide) 3120 mcg/1.56 mL penPA + QL 1.56 mLs per 30 days
    SPListed as SP with PA/QL on formulary line
    DispensingQL corresponds to single pen supply per month
    VOXZOGO QL
    VOXZOGO (vosoritide)PA + QL 30 vials per 30 days
    SPSpecialty handling indicated; PA required as noted
    Clinical noteQL set to expected monthly vial usage
    YORVIPATH QL
    YORVIPATH (palopegteriparatide) pensPA + QL 2 pens per 28 days
    SPListed as SP with PA/QL
    Dosing implicationQL reflects pen count per 28‑day period
    FUROSCIX QL
    FUROSCIX (furosemide subcutaneous kit)PA + QL 8 kits per 180 days
    Provider actionPrior authorization required; exceeding QL may lead to denial
    Use periodQL specified over 180‑day period
    NEXLETOL / NEXLIZET QL
    NEXLETOL / NEXLIZETPA + QL 30 tablets per 30 days
    REPATHAPA + QL 6 syringes per 28 days (6 syringes/28 days)
    Provider implicationPA and QL apply to lipid‑modifying specialty biologics
    REPATHA QL
    REPATHA (evolocumab)PA + QL 6 syringes per 28 days (6 syringes/28 days)
    REPATHA SURECLICKPA + QL 6 pens/28 days as listed
    Specialty handlingOften SP-managed; PA required when indicated
    ADEMPAS QL
    ADEMPAS (riociguat)PA + QL 90 tablets per 30 days
    UPTRAVI (selexipag)PA + QL 60 tablets per 30 days (titration packs also listed)
    PAH agentsMany PAH drugs list PA + QL and SP designations—adhere to Requirements/Limits
    UPTRAVI QL
    UPTRAVI (selexipag)PA + QL 60 tablets per 30 days (titration/pack QLs also shown)
    Titration packsSome entries show pack/180‑day QLs for titration kits
    SP designationSpecialty pharmacy handling commonly indicated
    Inhalers, nebulizers, specialty injectables QL examples
    Inhalers and nebulizersExamples: QL (3 inhalers/30 days); QL (2 inhalers/30 days); QL inhaler/30 days for many products
    Nebulizer solutionsExamples include QL 60 mLs/30 days; QL 120 vials/30 days depending on product
    Specialty injectablesMany specialty injectables list QL pen/28 days or QL syringe/56 days as applicable
    Esomeprazole QL
    Esomeprazole (Nexium) cap DRQL 60 capsules per 30 days
    Suspension/pack formsSuspension packets may have PA + QL 60 packets/30 days for some presentations
    Formulary noteCommon OTC‑equivalent PPI formulations carry explicit QL entries
    Sevelamer carbonate packet QL
    Sevelamer carbonate packets (Renvela) 0.8 gQL 1530 packets per 365 days
    Sevelamer HCl 400 mg tabletsQL 2880 tablets per 365 days
    Annual QL examplesLarge annual tablet/packet QLs are shown for renal phosphate binders
    Examples of oral psych/other QLs
    Oral psych and related agents (examples)Various QLs: QL 150 tablets/30 days; QL 60 tablets/30 days; QL 30 tablets/30 days depending on agent
    Clozapine (VERSACLOZ)QL 540 mLs per 30 days for suspension; ST may apply
    Risperidone, quetiapine, brexpiprazoleQL entries commonly 30–120 tablets/30 days depending on formulation
    FILSPARI; HETLIOZ QL examples
    FILSPARIQL 30 tablets per 30 days (example)
    HETLIOZ (tasimelteon oral suspension)PA + QL 158 mLs per 30 days or QL 30 capsules per 30 days for capsules
    SP/PA notesSome sleep agents carry PA and SP designations—adhere to line‑item requirements
    VERSACLOZ QL
    VERSACLOZ clozapine suspension 50 mg/mLQL 540 mLs per 30 days
    ST noteVERSACLOZ entries also list ST for certain formulations
    Special handlingMonitor QL adherence due to safety and monitoring requirements for clozapine
    Liraglutide (Saxenda) QL
    Saxenda (liraglutide) pen‑inj 18 mg/3 mLPA + QL 15 mLs per 30 days
    Weight‑management agentsMany are PA + QL (e.g., WEGOVY QL 8 pens/180 days or 4 pens/28 days)
    Provider actionPA required when noted; check line item for pen counts and mL QLs
    WEGOVY QL
    WEGOVY (semaglutide for weight management)PA + QL 8 pens per 180 days (or QL 4 pens/28 days depending on entry)
    ZEPBOUND (tirzepatide)QL examples: 4 pens/180 days or 4 pens/28 days for some packs; PA may apply
    Coverage noteWeight‑management biologics often require PA and have multi‑month QLs
    LYBALVI QL
    LYBALVI (olanzapine‑samidorphan)QL 30 tablets per 30 days
    Formulary noteListed with QL on formulary line—standard monthly tablet limit
    SP/PANoted SP/PA for some neuropsychiatric agents elsewhere in list
    NUEDEXTA QL
    NUEDEXTA (dextromethorphan‑quinidine)QL 60 capsules per 30 days
    Provider noteQL applies to chronic use indications; PA may be listed for other agents
    Formulary placementListed under neurological/psychotherapeutic agents with QL noted
    SODIUM OXYBATE QL
    Sodium oxybate (XYWAV/LUMRYZ)PA + QL 540 mLs per 30 days (example for sodium oxybate formulations)
    Starter/pack variationsStarter packs show separate QL (e.g., 28 packets/180 days) for initiation regimens
    SPOften SP-managed and PA required
    VUMERITY QL
    VUMERITY (diroximel fumarate)PA + QL 120 capsules per 30 days
    VYLEESI (bremelanotide)PA + QL 8 pens per 30 days
    SPListed as SP in many neurologic/rare disease agent entries
    VYLEESI QL
    VYLEESIPA + QL 8 pens per 30 days
    ZEPOSIA (ozanimod)PA + QL 30 capsules per 30 days (starter kits show 28 capsules/180 days for titration)
    SPSpecialty designation often accompanies PA/QL for these agents
    ZEPOSIA QL
    ZEPOSIA (ozanimod)PA + QL 30 capsules per 30 days; starter kit QL 28 capsules/180 days noted
    Starter kit7‑day or 28‑day starter kits have separate Requirements/Limits entries
    SPSpecialty pharmacy designation often applies
    BELBUCA / MORPHINE SULFATE ER QL
    BELBUCA (buprenorphine buccal film)QL 60 films per 30 days
    MORPHINE SULFATE ERQL 60 capsules per 30 days
    MS Contin (morphine ER)QL 90 tablets per 30 days for some ER formulations
    Tramadol / ADALIMUMAB / ENBREL QL examples
    Tramadol (Ultram) 50 mg tabsQL 240 tablets per 30 days
    Adalimumab products (biosimilars)QL typically 2 pens/syringes per 28 days (varies by brand/formulation)
    ENBREL (etanercept)QL 4 syringes per 28 days (or 4 injections/28 days for some presentations)

    Where Drugs Are Covered (Medical vs Pharmacy/Specialty)

    Note
    Note
    Note
    Note

    Key Terms & Acronyms

    Specialty drugs definition
    Specialty drugs definitionSpecialty drugs are medications for complex conditions that may require special handling or administration and may be covered differently (self‑administered vs clinician‑administered)
    Common characteristicsMay be oral, topical, or injectable; often require specialty pharmacy (SP) and prior authorization (PA)
    Reference sitesCurrent specialty drug lists available at MyPrime.com or bcbsok.com per formulary guidance
    Generic equivalent vs alternative
    Generic equivalent vs alternativeGeneric equivalent: same active ingredient and dosage as reference brand; Generic alternative: different active ingredient but used to treat the same condition
    Patient cost implicationMember may be responsible for cost difference if brand is requested over generic equivalent
    FDA standardGeneric drugs must meet same FDA standards as brand drugs
    QL definition
    QL — Quantity LimitMaximum quantity allowed in a specified period as shown on formulary (e.g., 'QL (30 tablets/30 days)')
    DL — Dispensing LimitDispensing limits may restrict quantity per prescription or over time; state laws may further restrict controlled substances
    ApplicationWhen QL/DL present, dispensing above the limit may require PA or be member‑paid unless exception granted
    PA definition
    PA — Prior AuthorizationApproval required before coverage; noted as 'PA' in Special Requirements column on formulary lines
    When requiredMany specialty, oncology, and selected branded agents (e.g., MOUNJARO, REPATHA, NEXLETOL) require PA
    Provider actionProviders must submit PA requests to the number on the member ID; documentation required per PA process
    SP definition
    SP — Specialty PharmacyDesignation for high‑cost or complex medications managed through specialty pharmacy channels (noted as 'SP' on formulary)
    ImplicationsSP products often require PA and have specific QLs; site‑of‑care and distribution may be specialized
    ReferenceSee specialty drug sections and MyPrime.com for specialty fulfillment details

    Examples of Authorization Triggers for Initiation

    Initial therapy authorization examples

    Selected lipid agents require authorization prior to initiation.

    Initiation requirements (excerpt): NEXLETOL and NEXLIZET require prior authorization and are subject to a 30 tablets/30 days quantity limit; REPATHA requires prior authorization with a 6 syringes/28 days limit.

    Full initiation clinical criteria and documentation requirements are managed through the PA process and are not detailed in this excerpt.

    Policy Background

    Specialty drugs are medications used to treat complex conditions (for example, hepatitis, hemophilia, multiple sclerosis, and rheumatoid arthritis). They may require special handling, administration, or patient support and can be self‑administered or clinician‑administered; products administered by a health care professional may be billed and covered under the medical benefit rather than the pharmacy benefit. The drug list is maintained by a clinical committee and classifies drugs by FDA‑approved indication while applying utilization controls where appropriate.